Core Viewpoint - The company, Yingmei Holdings (02028.HK), is expected to report a loss of between RMB 350 million to RMB 400 million for the six months ending June 30, 2025, compared to a loss of RMB 434.95 million in the same period last year [1] Group 1: Financial Performance - The anticipated loss for the upcoming period is attributed to a decline in printer demand, asset impairment provisions, and the lack of scale in medical product sales [1] - The company reported a significant loss of RMB 434.95 million in the previous year [1] Group 2: Market Activity - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on August 13, 2025 [1]

Company Performance - Maravai LifeSciences Holdings, Inc. reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -33.33% [1] - The company posted revenues of $47.4 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.23%, and a significant decline from year-ago revenues of $73.4 million [2] - Over the last four quarters, Maravai has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - Maravai LifeSciences shares have declined approximately 59.6% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $50.74 million, and for the current fiscal year, it is -$0.24 on revenues of $196.21 million [7] Industry Outlook - The Medical - Products industry, to which Maravai belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Maravai's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Insights - Myomo, Inc. reported a quarterly loss of $0.11 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.03 per share a year ago [1] - The company achieved revenues of $9.65 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.42%, and up from $7.52 million year-over-year [2] - Myomo shares have declined approximately 71.6% year-to-date, contrasting with the S&P 500's gain of 8.6% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - Myomo has topped consensus revenue estimates four times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $12.83 million, and -$0.16 on revenues of $50.34 million for the current fiscal year [7] Market Outlook - The Zacks Rank for Myomo is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The outlook for the Medical - Products industry, to which Myomo belongs, is currently in the bottom 38% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The correlation between near-term stock movements and earnings estimate revisions is emphasized, indicating that investors should monitor these trends closely [5]

Company Performance - SurModics reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.21 per share, and improved from a loss of $0.27 per share a year ago, representing an earnings surprise of +128.57% [1] - The company posted revenues of $29.57 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.29%, although this is a decline from year-ago revenues of $30.34 million [2] - Over the last four quarters, SurModics has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - SurModics shares have declined approximately 11.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $29.98 million, and for the current fiscal year, it is -$0.57 on revenues of $116.33 million [7] - The estimate revisions trend for SurModics was unfavorable prior to the earnings release, resulting in a Zacks Rank 5 (Strong Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which SurModics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - TerrAscend Corp. reported a quarterly loss of $0.03 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, marking an earnings surprise of -50.00% [1] - The company posted revenues of $65.01 million for the quarter ended June 2025, slightly surpassing the Zacks Consensus Estimate by 0.21%, but down from $77.52 million a year ago [2] - Over the last four quarters, TerrAscend has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - TerrAscend Corp. shares have declined approximately 24.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for TerrAscend is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $74.6 million, and for the current fiscal year, it is -$0.10 on revenues of $293.57 million [7] - The trend of estimate revisions for TerrAscend was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Products industry, to which TerrAscend belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Viewpoint - VAREX IMAGING reported quarterly earnings of $0.18 per share, significantly exceeding the Zacks Consensus Estimate of $0.04 per share, marking an earnings surprise of +350.00% [1][2] Financial Performance - The company achieved revenues of $203 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.73%, although this represents a decline from year-ago revenues of $209.1 million [2] - Over the last four quarters, VAREX IMAGING has consistently surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - VAREX IMAGING shares have declined approximately 51.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for VAREX IMAGING is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $199.03 million, while the estimate for the current fiscal year is $0.42 on revenues of $801.93 million [7] - The trend of estimate revisions for VAREX IMAGING was mixed prior to the earnings release, which may change following the recent results [6] Industry Context - The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Financial Performance - BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $25.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.98%, although this is a decline from year-ago revenues of $28.33 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - BioLife Solutions shares have declined approximately 18.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $24.55 million, and for the current fiscal year, it is $0.02 on revenues of $97.83 million [7] Industry Context - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Group 1 - Cresco Labs Inc. reported a quarterly loss of $0.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.16 per share a year ago, indicating a surprise of -25.00% [1] - The company posted revenues of $163.62 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.15%, and down from $184.36 million in the same quarter last year [2] - Cresco Labs Inc. shares have declined approximately 24.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Group 2 - The earnings outlook for Cresco Labs Inc. is uncertain, with current consensus EPS estimates at -$0.03 on revenues of $169.47 million for the upcoming quarter and -$0.11 on revenues of $675.98 million for the current fiscal year [7] - The Zacks Industry Rank places the Medical - Products sector in the bottom 37% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact stock performance [8] Group 3 - The estimate revisions trend for Cresco Labs Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Zimmer Biomet reported quarterly earnings of $2.07 per share, exceeding the Zacks Consensus Estimate of $1.98 per share, and showing an increase from $2.01 per share a year ago, resulting in an earnings surprise of +4.55% [1] - The company posted revenues of $2.08 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.59%, and an increase from $1.94 billion year-over-year [2] - Over the last four quarters, Zimmer has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - Zimmer shares have declined approximately 13.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.81 on revenues of $2 billion, and for the current fiscal year, it is $7.95 on revenues of $8.19 billion [7] Industry Context - The Medical - Products industry, to which Zimmer belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Company Performance - Prestige Consumer Healthcare reported quarterly earnings of $0.95 per share, missing the Zacks Consensus Estimate of $1.01 per share, representing an earnings surprise of -5.94% [1] - The company posted revenues of $249.53 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.73%, compared to year-ago revenues of $267.14 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Prestige Consumer Healthcare shares have lost about 3.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.19 on revenues of $290.86 million, and for the current fiscal year, it is $4.76 on revenues of $1.15 billion [7] Industry Context - The Medical - Products industry, to which Prestige Consumer Healthcare belongs, is currently in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5] - The unfavorable trend in estimate revisions prior to the earnings release has resulted in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]